ClinicalTrials.gg
CompletedNCT01307423PALACE4Updated Jun 14, 2022Results posted

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

A Phase 3 interventional study of Apremilast 20mg and Apremilast 30mg in Psoriatic Arthritis, sponsored by Amgen. Completed at 118 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-14.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
529
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing apremilast in Arthritis, Psoriatic — 3 open to participants now, 3 under way, 1 of them phase 3. apremilast · Arthritis, Psoriatic.

Enrollment
Largest of 17
529 · median 219
Started
2010
with 3 others
Phase 3
8 of 17
1 open now
Registered
5th of 17
by date
Lead sponsor
11 of 17
Amgen

Among the 17 studies testing apremilast in Arthritis, Psoriatic, this one has the largest enrollment, is one of 4 that started in 2010, is one of 8 in phase 3, and was the 5th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

3 of the 17 studies testing apremilast in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About apremilast

apremilast: first FDA approval 2014 (OTEZLA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing apremilast in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether apremilast is safe and effective in the treatment of patients with psoriatic arthritis who have not been previously treated with DMARDs.

Apremilast is proposed to improve signs and symptoms of psoriatic arthritis (tender and swollen joints, pain, physical function) in treated patients.

Read the detailed description

Psoriatic arthritis (PsA) is an inflammatory arthritis that occurs in 6-39% of psoriasis patients. The immunopathogenesis of PsA, which mirrors but is not identical to that seen in psoriatic plaques, reflects a complex interaction among resident dendritic, fibroblastic and endothelial cells, and inflammatory cells attracted to the synovium by cytokines and chemokines. Apremilast (CC-10004) is a novel oral agent that modulates multiple inflammatory pathways through targeted phosphodiesterase type 4 (PDE4) enzyme inhibition. Therefore, apremilast has the potential to be effective in the treatment of PsA.

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • psoriasis
  • Arthritis
  • Psoriatic Arthritis
  • inflammation
  • skin condition
  • inflammatory cells
  • apremilast
  • CC-10004
  • phosphodiesterase type 4
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Male or female, aged ≥ 18 years at time of consent.
  2. Must understand and voluntarily sign an document prior to any study related assessments/procedures being conducted.
  3. Able to adhere to the study visit schedule and other protocol requirements.
  4. Have a documented diagnosis of Psoriatic Arthritis (PsA, by any criteria) of ≥ 3 months duration.
  5. Meet the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria for PsA at time of screening.
  6. Have ≥ 3 swollen AND ≥ 3 tender joints.
  7. Have not been previously treated with disease-modifying antirheumatic drugs (DMARDS) (small molecules or biologics)
  8. Be receiving treatment on an outpatient basis.
  9. If taking oral , must be on a stable dose of prednisone ≤ 10 mg/day or equivalent for at least 1 month prior to screening.
  10. If taking nonsteroidal anti-inflammatory drugs (NSAIDs) or narcotic analgesics, must be on stable dose for at least 2 weeks prior to screening and until they have completed the Week 24 study visit.
  11. Low potency topical corticosteroids (Appendix M or locally available equivalent) will be allowed as background therapy for treatment of psoriasis on the face, axillae and groin in accordance with the manufacturers' suggested usage during the course of the study. Subjects with scalp psoriasis will be permitted to use coal tar shampoo and/or salicylic acid scalp preparations on scalp lesions. A non-medicated skin emollient (eg, Eucerin cream) will also be permitted for body lesions only. Subjects must not use these treatments within 24 hours prior to the clinic visit.
  12. Meet the following laboratory criteria:

    • White blood cell count ≥ 3000/mm3 (≥ 3.0 x 109/L) and \< 14,000/mm3 (\< 14 x 109/L)
    • count ≥ 100,000/mm3 (≥ 100 x 109/L)
    • Serum creatinine ≤ 1.5 mg/dL(≤ 132.6 μmol/L)
    • /Serum glutamic oxaloacetic transaminase (AST/SGOT) and Alanine aminotransferase/Serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 2 x (ULN)
    • Total ≤ 2 mg/dL (≤ 34 μmol/L)
    • ≥ 9 g/dL (≥ 5.6 mmol/L)
    • ≤ 9.0%
  13. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane]) while on IP and for at least 28 days after the last dose of IP.
  14. Females of (FCBP) must have a negative pregnancy test at Screening and Baseline. FCBP who engage in activity in which conception is possible must use 2 forms of contraception while on product (IP) and for at least 28 days after the last dose of IP: one highly effective form (ie, hormonal, intrauterine device [IUD], tubal ligation, vasectomized partner) and one additional form (latex condom or any nonlatex condom NOT made out of natural [animal] membrane [eg, polyurethane], diaphragm, sponge). If one highly effective form of contraception cannot be used, then 2 forms of barrier contraception must be used, ie, latex condom or any nonlatex condom NOT made out of natural (animal) membrane (eg, polyurethane) with either of the following: sponge with spermicide or diaphragm with spermicide.

Exclusion criteria

Exclusion Criteria:

  1. History of (as determined by the Investigator) cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic disease, or other major uncontrolled disease.
  2. Any condition, including the presence of laboratory abnormalities that places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  3. Clinically significant abnormality on 12-lead electrocardiography () at Screening.
  4. Pregnant or breast feeding.
  5. History of allergy to any component of the IP.
  6. surface antigen positive at screening.
  7. antibody positive at screening.
  8. /SGOT and/or ALT/SGPT > 1.5 x and total > ULN or albumin \< lower limit of normal (LLN).
  9. History of positive (HIV), or congenital or acquired immunodeficiency (eg, Common Variable Immunodeficiency Disease).
  10. Active tuberculosis or a history of incompletely treated tuberculosis.
  11. Clinically significant abnormality based upon chest radiograph with at least PA view (radiograph must be taken within 12 weeks prior to Screening or during the Screening visit). An additional lateral view is strongly recommended but not required.
  12. Active substance abuse or a history of substance abuse within 6 months prior to Screening.
  13. Bacterial infections requiring treatment with oral or injectable antibiotics, or significant viral or fungal infections, within 4 weeks of Screening. Any treatment for such infections must have been completed at least 4 weeks prior to Screening.
  14. or history of malignancy (except for treated [ie, cured] basal cell or squamous cell in situ skin carcinomas and treated [ie, cured] cervical intraepithelial neoplasia [CIN] or carcinoma in situ of the cervix).
  15. Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization.
  16. Erythrodermic, guttate, or pustular psoriasis.
  17. Topical therapy for psoriasis, except as noted in the Inclusion Criteria, within 2 weeks of randomization (including but not limited to topical , topical retinoids or vitamin D analog preparations, tacrolimus, pimecrolimus, or anthralin).
  18. Rheumatic disease other than PsA, including systemic lupus erythematosis (SLE), mixed connective tissue disease (MCTD), scleroderma, or polymyositis.
  19. Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis (Appendix Q).
  20. Prior history of or current inflammatory joint disease other than PsA (eg, gout, reactive arthritis, RA, ankylosing spondylitis, Lyme disease).
  21. Prior use of disease modifying antirheumatic drugs (DMARDS; small molecules or biologics).
  22. Use of the following systemic therapy(ies) within 4 weeks of randomization, including but not limited to corticosteroids (except as noted in inclusion criteria), oral retinoids and fumaric acid esters.
  23. Use of phototherapy within 4 weeks of randomization (ie, UVB, PUVA).
  24. Previous treatment with any cell depleting therapies, including agents (eg, rituximab, CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, and anti-CD20).
  25. Treatment with intravenous gamma globulin, plasmapheresis, or Prosorba® column within 6 months of baseline.
  26. Any previous treatment with alkylating agents such as cyclophosphamide or chlorambucil, or with total lymphoid irradiation.
  27. Prior treatment with apremilast.
  28. Use of any investigational drug within 4 weeks of randomization, or 5 pharmacokinetic/ pharmacodynamic half lives, if known (whichever is longer).
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
529 participants (actual)

Study arms

  • Experimental
    Apremilast 20mg

    Apremilast 20mg twice daily, orally

    Drug: Apremilast 20mg

  • Experimental
    Apremilast 30mg

    Apremilast 30mg twice daily, orally

    Drug: Apremilast 30mg

  • Placebo comparator
    Placebo + 20mg Apremilast

    Placebo + 20mg Apremilast tablets administered twice daily

    Drug: Apremilast 20mg · Drug: Placebo

  • Placebo comparator
    Placebo + 30mg Apremilast

    Placebo + 30mg Apremilast tablets administered twice daily

    Drug: Apremilast 30mg · Drug: Placebo

Interventions

  • Apremilast 20mg twice daily, orally

    Also known as: CC-10004

  • Apremilast 30mg twice daily, orally

    Also known as: CC-10004

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

    A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: -Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); -Patient's global assessment of disease activity (measured on a 100 mm VAS); -Physician's global assessment of disease activity (measured on a 100 mm VAS); -Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); -C-Reactive Protein.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 16

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 16

  2. Percentage of Participants With an ACR 20 Response at Week 24

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline and Week 24

  3. Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 24

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 24

  4. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  5. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 16

  6. Change From Baseline in Patient's Assessment of Pain at Week 16

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 16

  7. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  8. Change From Baseline in Dactylitis Severity Score at Week 16

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline to Week 16

  9. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22

    Time frame: Baseline and Week 16

  10. Change From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 16

  11. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 16

  12. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  13. Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

    Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

    Time frame: Baseline and Week 24

  14. Change From Baseline in Participants Assessment of Pain at Week 24

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 24

  15. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  16. Change From Baseline in Dactylitis Severity Score at Week 24

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  17. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

    Time frame: Baseline and Week 24

  18. Change From Baseline in Disease Activity Score (DAS 28) at Week 24

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 24

  19. Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 24

  20. Percentage of Participants With ≥ 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  21. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  22. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

    The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. Good or moderate response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2

    Time frame: Baseline and Week 16

  23. Percentage of Participants With MASES Improvement ≥ 20% at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  24. Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  25. Percentage of Participants With Good or Moderate EULAR Response at Week 24

    The EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on th DAS-28. Good or moderate response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2 A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

    Time frame: Baseline and Week 24

  26. Percentage of Participants With a ACR 50 Response at Week 16

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline and Week 16

  27. Percentage of Participants With a ACR 70 Response at Week 16

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline and Week 16

  28. Percentage of Participants With a ACR 50 Response at Week 24

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline and Week 24

  29. Percentage of Participants With a ACR 70 Response at Week 24

    Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

    Time frame: Baseline and Week 24

  30. Percentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 16

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 16

  31. Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 16

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 16

  32. Percentage of Participants Achieving a MASES Score of Zero at Week 24

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 24

  33. Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

    Time frame: Baseline and Week 24

  34. Percentage of Participants With a ACR 20 Response at Week 52

    Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count; ≥ 20% improvement in 76 swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  35. Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

    The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.

    Time frame: Baseline and Week 52

  36. Change From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 52

    The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  37. Percentage of Participants With a Modified PsARC Response at Week 52

    Measure Description: Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  38. Change From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52

    The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

    Time frame: Baseline and Week 52

  39. Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

    The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

    Time frame: Baseline and Week 52

  40. Change From Baseline in the Dactylitis Severity Score at Week 52

    Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present

    Time frame: Baseline and Week 52

  41. Change From Baseline in the CDAI Score at Week 52

    The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: 28 tender joint count (TJC), 28 swollen joint count (SJC), Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

    Time frame: Baseline and Week 52

  42. Change From Baseline in the DAS28 at Week 52

    The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

    Time frame: Baseline and Week 52

  43. Change From Baseline in the FACIT-Fatigue Scale Score at Week 52

    The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

    Time frame: Baseline and Week 52

  44. Percentage of Participants With MASES Improvement ≥ 20% at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  45. Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by ≥ 1 at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  46. Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52

    The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. A Good response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 A Moderate Response is defined as either: an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. Two-sided 95% confidence interval is based on the Clopper-Pearson method

    Time frame: Baseline and Week 52

  47. Percentage of Participants With an ACR 50 Response at Week 52

    Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 50% improvement in 78 tender joint count; ≥ 50% improvement in 76 swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  48. Percentage of Participants With an ACR 70 Response at Week 52

    A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 70% improvement in 78 tender joint count; ≥ 70% improvement in 76 swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  49. Percentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 52

    Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval was based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  50. Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 52

    Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 20. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

    Time frame: Baseline and Week 52

  51. Number of Participants With Treatment Emergent Adverse Events During the Placebo Controlled Phase

    A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

    Time frame: Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)

  52. Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

    A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

    Time frame: Week 0 to Week 260; median duration of exposure to apremilast 20 mg BID was 168.93 weeks and 229.36 weeks for apremilast 30 mg BID

07

Results

Posted Aug 15, 2014

Participant flow

The study was conducted in 16 countries including the United States, Canada, Europe, New Zealand, Australia and Russia.

Placebo-controlled Phase (Week 0 - 24)
Participant flow — Placebo-controlled Phase (Week 0 - 24)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started176175177000000
Received treatment176175175000000
Completed week 16166168166000000
Early escape at week 161037379000000
Completed156160155000000
Not completed201522000000
Withdrew: Adverse event446000000
Withdrew: Lack of efficacy132000000
Withdrew: Withdrawal by subject8410000000
Withdrew: Randomization error001000000
Withdrew: Lost to follow-up512000000
Withdrew: Protocol violation100000000
Withdrew: Other120000000
Withdrew: Non-compliance with study drug011000000
Active Treatment Phase (Week 25-52)
Participant flow — Active Treatment Phase (Week 25-52)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started01511504626462600
Completed01321413823432500
Not completed0199833100
Withdrew: Adverse event032220000
Withdrew: Lack of efficacy055310000
Withdrew: Non-compliance with study drug000001000
Withdrew: Withdrawal by subject0112001100
Withdrew: Lost to follow-up000200000
Withdrew: Other000100000
Withdrew: Protocol violation000001000
Long-term Safety Phase (Year 2)
Participant flow — Long-term Safety Phase (Year 2)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started012213400005767
Completed09910900004860
Not completed02325000097
Withdrew: Adverse event027000011
Withdrew: Lack of efficacy075000043
Withdrew: Noncompliance with study drug001000000
Withdrew: Withdrawal by subject01312000032
Withdrew: Miscellaneous010000011
Long-term Safety Phase (Year 3)
Participant flow — Long-term Safety Phase (Year 3)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started09910900004860
Completed0909100004049
Not completed09180000811
Withdrew: Adverse event012000034
Withdrew: Lack of efficacy024000012
Withdrew: Noncompliance with study drug011000000
Withdrew: Withdrawal by subject028000024
Withdrew: Lost to follow-up023000011
Withdrew: Miscellaneous010000010
Long-term Safety Phase (Year 4)
Participant flow — Long-term Safety Phase (Year 4)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0899100004049
Completed0818600003844
Not completed085000025
Withdrew: Adverse event020000000
Withdrew: Lack of efficacy010000001
Withdrew: Withdrawal by subject054000014
Withdrew: Lost to follow-up001000000
Withdrew: Miscellaneous000000010
Long-term Safety Phase (Year 5)
Participant flow — Long-term Safety Phase (Year 5)
MilestonePlaceboApremilast 20 mgApremilast 30 mgPlacebo/ Apremilast 20 mg EEPlacebo / Apremilast 20 mg XOPlacebo / Apremilast 30 mg EEPlacebo / Apremilast 30 mg XOPlacebo/Apremilast 20 mg [Long-Term Safety Phase (LTSP)]Placebo/Apremilast 30 mg (Long-Term Safety Phase)
Started0818600003844
Completed0718000003741
Not completed0106000013
Withdrew: Adverse event011000001
Withdrew: Lack of efficacy021000000
Withdrew: Withdrawal by subject062000001
Withdrew: Lost to follow-up010000000
Withdrew: Miscellaneous002000011

Outcome measures

PrimaryPercentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16

A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: -Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); -Patient's global assessment of disease activity (measured on a 100 mm VAS); -Physician's global assessment of disease activity (measured on a 100 mm VAS); -Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); -C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlaceboApremilast 20mgApremilast 30mg
Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 1615.928.030.7
Statistical analysis
  • Placebo vs Apremilast 20mg · Chi-squared · p = 0.0062 · Risk difference (rd): 12.1 · 95% CI 3.5 to 20.7Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30mg · Chi-squared · p = 0.0010 · Risk difference (rd): 14.8 · 95% CI 6.1 to 23.5Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 16

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30mg
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 160.012 ± 0.0350-0.156 ± 0.0349-0.205 ± 0.0350
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0008 · Ls mean difference: -0.168 · 95% CI -0.265 to -0.071Based on an analysis of covariance (ANCOVA) model with treatment group as a factor, and the baseline value as a covariate.
  • Placebo vs Apremilast 30mg · ANCOVA · p = <.0001 · Ls mean difference: -0.217 · 95% CI -0.314 to -0.120Based on an analysis of covariance (ANCOVA) model with treatment group as a factor, and the baseline value as a covariate
SecondaryPercentage of Participants With an ACR 20 Response at Week 24

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from baseline were met: • ≥ 20% improvement in 78 tender joint count; • ≥ 20% improvement in 76 swollen joint count; and • ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With an ACR 20 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 20 Response at Week 2413.129.124.4
Statistical analysis
  • Placebo vs Apremilast 20 mg · Chi-squared · p = 0.0002 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Risk difference (rd): 16.1 · 95% CI 7.7 to 24.4Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Chi-squared · p = 0.0063 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Risk difference (rd): 11.4 · 95% CI 3.3 to 19.4Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryChange From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 24

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire- Disability Index [HAQ-DI]) at Week 240.012 ± 0.0370-0.156 ± 0.0368-0.207 ± 0.0369
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0014 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: -0.168 · 95% CI -0.271 to -0.065Based on an analysis of covariance model for the change from baseline at Week 24, with treatment group as a factor and baseline value as a covariate
  • Placebo vs Apremilast 30 mg · ANCOVA · p = <.0001 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: -0.219 · 95% CI -0.322 to -0.117Based on an analysis of covariance model for the change from baseline at Week 24, with treatment group as a factor and baseline value as a covariate
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 160.01 ± 0.5882.39 ± 0.5863.19 ± 0.590
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0043 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Ls mean difference: 2.38 · 95% CI 0.75 to 4.01Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and baseline value as a covariate
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0002 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: 3.18 · 95% CI 1.55 to 4.82Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and baseline value as a covariate
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 1624.438.945.5
Statistical analysis
  • Placebo vs Apremilast 20 mg · Chi-squared · p = 0.0037 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Risk difference (rd): 14.4 · 95% CI 4.8 to 24.0Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Chi-squared · p = <.0001 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above.) · Risk difference (rd): 21.0 · 95% CI 11.3 to 30.7Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryChange From Baseline in Patient's Assessment of Pain at Week 16

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · mm
Change From Baseline in Patient's Assessment of Pain at Week 16
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Patient's Assessment of Pain at Week 16-2.6 ± 1.81-7.7 ± 1.79-10.5 ± 1.80
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.0485 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: -5.0 · 95% CI -10.0 to -0.0Based on an analysis of covariance (ANCOVA) model with treatment group as a factor, and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0022 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: -7.8 · 95% CI -12.8 to -2.8Based on an analysis of covariance (ANCOVA) model with treatment group as a factor, and the baseline value as a covariate
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 16-0.5 ± 0.24-0.5 ± 0.24-1.5 ± 0.25
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = 0.7696 · Ls mean difference: -0.1 · 95% CI -0.8 to 0.6Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0038 (Secondary endpoints from the placebo-controlled period (Weeks 16 and 24) were analyzed in a hierarchical fashion to control the Type I error rate as described above) · Ls mean difference: -1.0 · 95% CI -1.7 to -0.3Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in Dactylitis Severity Score at Week 16

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 16-1.0 ± 0.25-1.9 ± 0.25-1.7 ± 0.26
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.9 · 95% CI -1.6 to -0.2Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.7 · 95% CI -1.4 to -0.0Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 16

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 16-1.98 ± 0.770-6.89 ± 0.763-7.63 ± 0.768
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -4.91 · 95% CI -7.04 to -2.78Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · Ls mean difference: -5.65 · 95% CI -7.78 to -3.51Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Disease Activity Score (DAS28) After 16 Weeks of Treatment-0.15 ± 0.076-0.61 ± 0.076-0.68 ± 0.075
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.46 · 95% CI -0.67 to -0.25Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.53 · 95% CI -0.74 to -0.32Based on analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 16
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 160.07 ± 0.6311.19 ± 0.6292.62 ± .0633
Statistical analysis
  • Placebo vs Apremilast 20 mg · Difference in ls means: 1.12 · 95% CI -0.63 to 2.87Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · Difference in ls means: 2.55 · 95% CI 0.80 to 4.31Based on an analysis of covariance model for the change from baseline at Week 16, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). SF-36 domain scores were first calculated to range from 0 to100 and then transformed to norm-based scores (the norm-based scores in the US general population have an average of 50 and a standard deviation of 10). Norm-based scores were used in analyses, with higher scores indicating a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Functioning Domain at Week 240.16 ± 0.6092.13 ± 0.6053.88 ± 0.611
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls means difference: 1.97 · 95% CI 0.28 to 3.65Based on an analysis of covariance model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · Ls mean difference: 3.72 · 95% CI 2.02 to 5.41Based on an analysis of covariance model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate
SecondaryPercentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24

Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified Psoriatic Arthritis Response Criteria (PsARC) Response at Week 2417.036.635.2
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 19.5 · 95% CI 10.5 to 28.6Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 18.2 · 95% CI 9.2 to 27.2Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
SecondaryChange From Baseline in Participants Assessment of Pain at Week 24

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mm
Change From Baseline in Participants Assessment of Pain at Week 24
mmPlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Participants Assessment of Pain at Week 24-3.8 ± 1.83-9.4 ± 1.82-9.6 ± 1.83
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -5.6 · 95% CI -10.6 to -0.5Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate
  • Placebo vs Apremilast 30 mg · Ls mean difference: -5.7 · 95% CI -10.8 to -0.7Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 24-0.6 ± 0.25-0.9 ± 0.25-1.5 ± 0.26
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -0.3 · 95% CI -1.0 to 0.4Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.9 · 95% CI -1.6 to -0.2Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
SecondaryChange From Baseline in Dactylitis Severity Score at Week 24

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dactylitis Severity Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Dactylitis Severity Score at Week 24-1.0 ± 0.26-2.0 ± 0.26-1.7 ± 0.27
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -1.0 · 95% CI -1.7 to -0.3Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
  • Placebo vs Apremilast 30 mg · Ls mean difference: -0.6 · 95% CI -1.4 to 0.1Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 24

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: • 28 tender joint count (TJC), • 28 swollen joint count (SJC), • Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; • Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8; Low Disease Activity: \> 2.8 and ≤ 10; Moderate Disease Activity: \> 10 and ≤ 22; High Disease Activity: \> 22.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 24-2.23 ± 0.807-7.30 ± 0.803-7.36 ± 0.810
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: -5.07 · 95% CI -7.31 to -2.84Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
  • Placebo vs Apremilast 30 mg · Ls mean difference: -5.14 · 95% CI -7.38 to -2.89Based on an analysis of covariance model (Ancova) for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
SecondaryChange From Baseline in Disease Activity Score (DAS 28) at Week 24

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Disease Activity Score (DAS 28) at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in Disease Activity Score (DAS 28) at Week 24-0.22 ± 0.084-0.69 ± 0.084-0.68 ± 0.084
Statistical analysis
  • Placebo vs Apremilast 20 mg · ANCOVA · p = <0.0001 · Ls mean difference: -0.47 · 95% CI -0.70 to -0.23Based on an analysis of covariance (Ancova) model for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
  • Placebo vs Apremilast 30 mg · ANCOVA · p = 0.0001 · Ls mean difference: -0.46 · 95% CI -0.69 to -0.22Based on an analysis of covariance model (Ancova) for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
SecondaryChange From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 24
units on a scalePlaceboApremilast 20 mgApremilast 30 mg
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Score at Week 240.25 ± 0.6521.37 ± 0.6482.58 ± 0.655
Statistical analysis
  • Placebo vs Apremilast 20 mg · Ls mean difference: 1.12 · 95% CI -0.68 to 2.93Based on an analysis of covariance model (Ancova) for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
  • Placebo vs Apremilast 30 mg · Ls mean difference: 2.33 · 95% CI 0.52 to 4.15Based on an analysis of covariance model (Ancova) for the change from baseline at Week 24, with treatment group as a factor and the baseline value as a covariate.
SecondaryPercentage of Participants With ≥ 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With ≥ 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With ≥ 20% Improvement in Maastricht Ankylosing Spondylitis Entheses Score at Week 1646.148.763.1
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 2.6 · 95% CI -10.2 to 15.5Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 17.0 · 95% CI 4.2 to 29.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 1660.066.361.9
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 6.3 · 95% CI -7.8 to 20.4Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 1.9 · 95% CI -12.6 to 16.4Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16

The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. Good or moderate response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Response at Week 1625.041.144.3
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 16.1 · 95% CI 6.4 to 25.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 19.3 · 95% CI 9.6 to 29.1Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 2448.754.766.7
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 6.0 · 95% CI -6.8 to 18.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 18.0 · 95% CI 5.3 to 30.6Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
SecondaryPercentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Dactylitis Improvement ≥ 1 Point at Week 2457.869.763.1
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 11.9 · 95% CI -2.1 to 25.9Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 5.3 · 95% CI -9.2 to 19.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Good or Moderate EULAR Response at Week 24

The EULAR response reflects an improvement in disease activity and an attainment of a lower degree of disease activity based on th DAS-28. Good or moderate response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 Moderate response: DAS28 at the time point \> 3.2 and improvement from baseline \> 1.2, or DAS28 at the time point ≤ 5.1 and improvement from baseline \> 0.6 and ≤ 1.2 A Moderate Response is defined as either: • an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, • an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate EULAR Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Good or Moderate EULAR Response at Week 2417.034.928.4
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 17.8 · 95% CI 8.8 to 26.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 11.4 · 95% CI 2.7 to 20.0Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With a ACR 50 Response at Week 16

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With a ACR 50 Response at Week 16
Percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 50 Response at Week 164.511.411.4
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 6.9 · 95% CI 1.3 to 12.5Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 6.8 · 95% CI 1.2 to 12.4Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With a ACR 70 Response at Week 16

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 70 Response at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 70 Response at Week 161.14.04.0
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 2.9 · 95% CI -0.4 to 6.2Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 2.8 · 95% CI -0.4 to 6.1Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
SecondaryPercentage of Participants With a ACR 50 Response at Week 24

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 50% improvement in 78 tender joint count; • ≥ 50% improvement in 76 swollen joint count; and • ≥ 50% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 50 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 50 Response at Week 246.316.012.5
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 9.8 · 95% CI 3.2 to 16.3Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 6.3 · 95% CI 0.2 to 12.3Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution
SecondaryPercentage of Participants With a ACR 70 Response at Week 24

Percentage of participants with an American College of Rheumatology 70% (ACR70) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: • ≥ 70% improvement in 78 tender joint count; • ≥ 70% improvement in 76 swollen joint count; and • ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With a ACR 70 Response at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30mg
Percentage of Participants With a ACR 70 Response at Week 244.04.04.5
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 0.0 · 95% CI -4.1 to 4.1Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30mg · Risk difference (rd): 0.6 · 95% CI -3.7 to 4.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 16

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 16 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants With Pre-existing Enthesopathy Whose Maastricht Ankylosing Spondylitis Entheses Score Improves to 0 at Week 1619.121.436.9
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 2.2 · 95% CI -8.1 to 12.6Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 17.8 · 95% CI 6.3 to 29.3Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 16

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 16 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 16
percentage of participantsPlaceboApremilast 20 mgApremilast 30mg
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves to 0 at Week 1633.342.740.5
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 9.4 · 95% CI -4.8 to 23.5Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30mg · Risk difference (rd): 7.1 · 95% CI -7.2 to 21.5Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants Achieving a MASES Score of Zero at Week 24

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks of treatment. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a MASES Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a MASES Score of Zero at Week 2422.629.137.8
Statistical analysis
  • Placebo vs Apremilast 20 mg · Risk difference (rd): 6.5 · 95% CI -4.8 to 17.7Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 15.2 · 95% CI 3.4 to 27.1Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants Achieving a Dactylitis Score of Zero at Week 24

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 24 weeks of treatment. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present.

Time frame:
Baseline and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 24
percentage of participantsPlaceboApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving a Dactylitis Score of Zero at Week 2435.646.140.5
Statistical analysis
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 10.5 · 95% CI -3.8 to 24.8Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
  • Placebo vs Apremilast 30 mg · Risk difference (rd): 4.9 · 95% CI -9.5 to 19.3Two-sided 95% CI of the proportion difference is based on the normal approximation to the binomial distribution.
SecondaryPercentage of Participants With a ACR 20 Response at Week 52

Percentage of participants with an American College of Rheumatology 20% (ACR20) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 20% improvement in 78 tender joint count; ≥ 20% improvement in 76 swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With a ACR 20 Response at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a ACR 20 Response at Week 5259.7 (46.4 to 71.9)56.7 (44.0 to 68.8)53.4 (44.5 to 62.2)58.7 (50.0 to 67.0)
SecondaryChange From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52

The Health Assessment Questionnaire - Disability Index is a patient-reported questionnaire consisting of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task are summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. Negative changes from Baseline in the overall score indicate improvement in functional ability.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Week 52-0.21 ± 0.450-0.25 ± 0.533-0.32 ± 0.559-0.39 ± 0.567
SecondaryChange From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 52

The Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) is a self-administered instrument that measures the impact of disease on overall quality of life and consists of 36 questions in eight domains (physical function, pain, general and mental health, vitality, social function, physical and emotional health). Norm-based scores were used in analyses, calibrated so that 50 is the average score and the standard deviation equals 10. Higher scores indicate a higher level of functioning. The physical functioning domain assesses limitations in physical activities because of health problems. A positive change from Baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the SF-36v2 Physical Functioning Scale Score at Week 527.76 ± 8.2366.87 ± 7.2415.68 ± 8.4675.87 ± 8.008
SecondaryPercentage of Participants With a Modified PsARC Response at Week 52

Measure Description: Modified PsARC response is defined as improvement in at least 2 of the 4 measures, at least one of which must be tender joint count or swollen joint count, and no worsening in any of the 4 measures: • 78 tender joint count, • 76 swollen joint count, • Patient global assessment of disease activity, measured on a 100 mm visual Analog scale (VAS), where 0=lowest disease activity and 100=highest; • Physician global assessment of disease activity, measured on a 100 mm VAS, where 0=lowest disease activity and 100=highest. Improvement or worsening in joint counts is defined as decrease or increase, respectively, from baseline by ≥ 30%, and improvement or worsening in global assessments is defined as decrease or increase, respectively, from baseline by ≥ 20 mm VAS. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Modified PsARC Response at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With a Modified PsARC Response at Week 5273.8 (60.9 to 84.2)79.1 (67.4 to 88.1)75.6 (67.3 to 82.7)75.9 (67.9 to 82.8)
SecondaryChange From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52

The participant was asked to place a vertical line on a 100-mm visual analog scale on which the left-hand boundary (score = 0 mm) represents "no pain," and the right-hand boundary (score = 100 mm) represents "pain as severe as can be imagined." The distance from the mark to the left-hand boundary was recorded in millimeters.

Time frame:
Baseline and Week 52
Reported as:
Mean · mm
Change From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52
mmPlacebo/Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Participants Assessment of Pain Using the Visual Analog Scale at Week 52-13.1 ± 25.57-18.9 ± 24.28-15.6 ± 27.29-14.2 ± 28.14
SecondaryChange From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52

The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo/Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in Maastricht Ankylosing Spondylitis Entheses Score (MASES) at Week 52-1.7 ± 2.38-1.8 ± 2.34-1.5 ± 2.62-1.8 ± 3.03
SecondaryChange From Baseline in the Dactylitis Severity Score at Week 52

Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet will be rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the Dactylitis Severity Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the Dactylitis Severity Score at Week 52-2.2 ± 1.89-2.9 ± 2.47-2.2 ± 4.09-2.9 ± 3.55
SecondaryChange From Baseline in the CDAI Score at Week 52

The Clinical Disease Activity Index (CDAI) is a composite index that is calculated as the sum of the: 28 tender joint count (TJC), 28 swollen joint count (SJC), Patient's Global Assessment of Disease Activity measured on a 10 cm visual analog scale (VAS), where 0 cm = lowest disease activity and 10 cm = highest; Physician's Global Assessment of Disease Activity -measured on a 10 cm VAS, where 0 cm = lowest disease activity and 10 cm = highest. The CDAI score ranges from 0-76 where lower scores indicate less disease activity. The following thresholds of disease activity have been defined for the CDAI: Remission: ≤ 2.8 Low Disease Activity: \> 2.8 and ≤ 10 Moderate Disease Activity: \> 10 and ≤ 22 High Disease Activity: \> 22.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the CDAI Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the CDAI Score at Week 52-11.0 ± 10.288-14.67 ± 11.943-14.32 ± 11.128-13.98 ± 10.541
SecondaryChange From Baseline in the DAS28 at Week 52

The DAS28 measures the severity of disease at a specific time and is derived from the following variables: • 28 tender joint count • 28 swollen joint count, which do not include the DIP joints, the hip joint, or the joints below the knee; • C-reactive protein (CRP) • Patient's global assessment of disease activity. DAS28(CRP) scores range from 0 to approximately 10, with the upper bound dependent on the highest possible level of CRP. A DAS28 score higher than 5.1 indicates high disease activity, a DAS28 score less than 3.2 indicates low disease activity, and a DAS28 score less than 2.6 indicates clinical remission.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the DAS28 at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the DAS28 at Week 52-1.08 ± 1.113-1.28 ± 1.044-1.37 ± 1.128-1.39 ± 0.970
SecondaryChange From Baseline in the FACIT-Fatigue Scale Score at Week 52

The FACIT-Fatigue scale is a 13-item self-administered questionnaire that assesses both the physical and functional consequences of fatigue. Each question is answered on a 5-point scale, where 0 means "not at all," and 4 means "very much." The FACIT-Fatigue scale score ranges from 0 to 52, with higher scores denoting lower levels of fatigue. A positive change from baseline score indicates an improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in the FACIT-Fatigue Scale Score at Week 52
units on a scalePlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Change From Baseline in the FACIT-Fatigue Scale Score at Week 526.03 ± 8.7874.27 ± 9.4612.39 ± 10.1975.89 ± 10.471
SecondaryPercentage of Participants With MASES Improvement ≥ 20% at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improved by ≥ 20% from Baseline after 52 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With MASES Improvement ≥ 20% at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With MASES Improvement ≥ 20% at Week 5270.7 (54.5 to 83.9)81.0 (65.9 to 91.4)65.9 (55.3 to 75.5)69.4 (58.5 to 79.0)
SecondaryPercentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by ≥ 1 at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improved by ≥ 1 after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit. The dactylitis severity score, ranging from 0 to 20, is the number of digits on the hands and feet with dactylitis present. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by ≥ 1 at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline by ≥ 1 at Week 5293.8 (79.2 to 99.2)94.7 (82.3 to 99.4)87.1 (77.0 to 93.9)85.9 (75.0 to 93.4)
SecondaryPercentage of Participants Achieving Good or Moderate EULAR Response at Week 52

The EULAR response criteria classify each subject as a good, moderate or non-responder to treatment based on the degree of improvement from baseline and the level of disease activity at the endpoint. EULAR response is derived using the individual subject's DAS28 as the measure of severity of disease. A Good response is defined as follows: Good response: DAS28 at the time point ≤ 3.2 and improvement from baseline \> 1.2 A Moderate Response is defined as either: an improvement (decrease) in the DAS28 of greater than 0.6 and less than or equal to 1.2 and attainment of a DAS28 score of less than or equal to 5.1 or, an improvement (decrease) in the DAS28 of more than 1.2 and attainment of a DAS28 score of greater than 3.2. Two-sided 95% confidence interval is based on the Clopper-Pearson method

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants Achieving Good or Moderate EULAR Response at Week 5264.573.575.479.0
SecondaryPercentage of Participants With an ACR 50 Response at Week 52

Percentage of participants with an American College of Rheumatology 50% (ACR50) response. A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 50% improvement in 78 tender joint count; ≥ 50% improvement in 76 swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: o Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an ACR 50 Response at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 50 Response at Week 5230.6 (19.6 to 43.7)25.4 (15.5 to 37.5)27.1 (19.7 to 35.7)31.9 (24.2 to 40.4)
SecondaryPercentage of Participants With an ACR 70 Response at Week 52

A participant was a responder if the following 3 criteria for improvement from Baseline were met: ≥ 70% improvement in 78 tender joint count; ≥ 70% improvement in 76 swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: Patient's assessment of pain (measured on a 100 mm visual analog scale \[VAS\]); Patient's global assessment of disease activity (measured on a 100 mm VAS); Physician's global assessment of disease activity (measured on a 100 mm VAS); Patient's self-assessment of physical function (Health Assessment Questionnaire - Disability Index (HAQ-DI)); C-Reactive Protein. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With an ACR 70 Response at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With an ACR 70 Response at Week 528.2 (2.7 to 18.1)10.3 (4.2 to 20.1)13.7 (8.4 to 20.8)18.1 (12.1 to 25.6)
SecondaryPercentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 52

Percentage of participants with pre-existing enthesopathy whose MASES improves to 0 after 24 weeks. The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Achilles tendon left/right. The MASES, ranging from 0 to 13, is the number of painful entheses out of 13 entheses. Two-sided 95% confidence interval was based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 52
percentage of participantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Pre-existing Enthesopathy Whose MASES Improves From Baseline to 0 at Week 5239.0 (24.2 to 55.5)61.9 (45.6 to 76.4)39.6 (29.5 to 50.4)45.9 (35.0 to 57.0)
SecondaryPercentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 52

Percentage of participants with pre-existing dactylitis whose dactylitis severity score improves to zero after 52 weeks. Dactylitis is characterized by swelling of the entire finger or toe. Each digit on the hands and feet was rated as zero for no dactylitis or 1 for dactylitis present. The dactylitis severity score is the sum of the individual scores for each digit and ranges from 0 to 20. Two-sided 95% confidence interval is based on the Clopper-Pearson method.

Time frame:
Baseline and Week 52
Reported as:
Number · Percentage of Participants
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 52
Percentage of ParticipantsPlacebo / Apremilast 20 mgPlacebo / Apremilast 30 mgApremilast 20 mgApremilast 30 mg
Percentage of Participants With Pre-existing Dactylitis Whose Dactylitis Severity Score Improves From Baseline to 0 at Week 5275.0 (56.6 to 88.5)78.9 (62.7 to 90.4)68.6 (56.4 to 79.1)68.8 (55.9 to 79.8)
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Placebo Controlled Phase

A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

Time frame:
Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants (placebo participants who remained on placebo through week 24 and participants randomized to the APR 20 mg BID or APR 30 mg BID)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Placebo Controlled Phase
ParticipantsPlaceboApremilast 20mgApremilast 30mg
Any TEAE738799
Any Drug-Related TEAE254058
Any Severe TEAE642
Any Serious TEAE (SAE)531
Drug-Related (SAE)001
Any TEAE Leading to Drug Interruption8119
Any TEAE Leading to Drug Withdrawal446
Any TEAE Leading to Death000
SecondaryNumber of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period

A TEAE is an adverse event (AE) with a start date on or after the date of the first dose of investigational product (IP) and no later than 28 days after the last dose of IP. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. A serious AE is any AE that results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or constitutes an important medical event. For both AEs and SAEs the investigator assessed the severity of the event according to the grading scale: Mild: asymptomatic or with mild symptoms, Moderate: symptoms causing moderate discomfort or Severe: symptoms causing severe discomfort or pain.

Time frame:
Week 0 to Week 260; median duration of exposure to apremilast 20 mg BID was 168.93 weeks and 229.36 weeks for apremilast 30 mg BID
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
ParticipantsApremilast 20 mg (Pre-Switch)Apremilast 20/30 mg (Post-Switch)Apremilast 30 mg
Any TEAE18860204
Any Drug-Related TEAE8916113
Any Severe TEAE24323
Any Serious TEAE (SAE)35536
Drug-Related (SAE)616
Any TEAE Leading to Drug Interruption41536
Any TEAE Leading to Drug Wirhdrawal22226
Any TEAE Leading to Death000

Adverse events

Collected over AEs are reported for the placebo-controlled phase from Week 0 to Week 16 for placebo participants who entered EE at Week 16 and up to Week 24 for all other participants and reported for the Apremilast Exposure Period from Week 0 to Week 260; median duration of apremilast 20 mg BID was 168.93 weeks and 229.36 weeks for apremilast 30 mg twice daily. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Weeks 0-24: Placebo (Placebo-Controlled Phase)—5/176 (2.8%)30/176 (17%)
Weeks 0-24: Apremilast 20 mg—3/175 (1.7%)51/175 (29.1%)
Weeks 0-24: Apremilast 30 mg—1/175 (0.6%)65/175 (37.1%)
APR Exposure Period Up to 5 Years: Apremilast 20 mg—35/252 (13.9%)121/252 (48%)
APR Exposure Period Up to 5 Years: Apremilast 20mg/30 mg—5/122 (4.1%)24/122 (19.7%)
APR Exposure Period Up to 5 Years: Apremilast 30 mg—36/252 (14.3%)141/252 (56%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mgWeeks 0-24: Apremilast 30 mgAPR Exposure Period Up to 5 Years: Apremilast 20 mgAPR Exposure Period Up to 5 Years: Apremilast 20mg/30 mgAPR Exposure Period Up to 5 Years: Apremilast 30 mg
Inguinal herniaGastrointestinal disorders0/1760/1750/1751/2521/1223/252
Clostridium difficile colitisInfections and infestations0/1760/1750/1750/2521/1220/252
Meningitis bacterialInfections and infestations0/1760/1750/1750/2521/1220/252
Pneumococcal bacteraemiaInfections and infestations0/1760/1750/1750/2521/1220/252
PneumoniaInfections and infestations0/1760/1750/1750/2521/1220/252
Incisional herniaInjury, poisoning and procedural complications1/1760/1750/1751/2521/1220/252
Angina pectorisCardiac disorders0/1760/1750/1751/2520/1222/252
Atrial flutterCardiac disorders0/1760/1750/1750/2520/1222/252
Coronary artery diseaseCardiac disorders0/1760/1750/1751/2520/1222/252
Umbilical herniaGastrointestinal disorders0/1760/1750/1750/2520/1222/252
Most frequent other events
Showing 10 of 13
Most frequent other events
EventWeeks 0-24: Placebo (Placebo-Controlled Phase)Weeks 0-24: Apremilast 20 mgWeeks 0-24: Apremilast 30 mgAPR Exposure Period Up to 5 Years: Apremilast 20 mgAPR Exposure Period Up to 5 Years: Apremilast 20mg/30 mgAPR Exposure Period Up to 5 Years: Apremilast 30 mg
NauseaGastrointestinal disorders5/17616/17528/17524/2522/12239/252
DiarrhoeaGastrointestinal disorders3/17612/17521/17530/2522/12231/252
Upper respiratory tract infectionInfections and infestations4/1766/1757/17526/2525/12231/252
HeadacheNervous system disorders4/1766/17515/17515/2520/12226/252
NasopharyngitisInfections and infestations3/1763/1753/17520/2525/12223/252
Urinary tract infectionInfections and infestations1/1762/1752/17510/2523/12218/252
SinusitisInfections and infestations1/1766/1754/17516/2526/12212/252
HypertensionVascular disorders1/1764/1754/17515/2520/12216/252
DyspepsiaGastrointestinal disorders2/1768/1750/17514/2520/1224/252
Back painMusculoskeletal and connective tissue disorders0/1761/1753/17514/2520/12210/252

Baseline characteristics

Full Analysis Set was defined as participants who were randomized as specified in the protocol; one participant who was randomized in error and did not receive any dose of investigational product was excluded.

Age, Continuous
Age, Continuous(years)PlaceboApremilast 20mgApremilast 30mgTotal
Mean50.5 ± 11.5849.2 ± 12.0048.4 ± 12.5249.4 ± 12.05
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboApremilast 20mgApremilast 30mgTotal
Female869596277
Male908080250
Duration of Psoriatic Arthritis
Duration of Psoriatic Arthritis(years)PlaceboApremilast 20mgApremilast 30mgTotal
Mean3.42 ± 5.1033.19 ± 4.7063.62 ± 5.0413.41 ± 4.947
08

Study locations

118 sites
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • In Vivo Clinical Research
    Doral, Florida 33166, United States
  • Centre For Rheumatology, Immun. And Arthritis
    Fort Lauderdale, Florida 33334, United States
  • North Florida Dermatology
    Jacksonville, Florida 32204, United States
  • Florida Center for Dermatology, PA
    Saint Augustine, Florida 32086, United States
  • Tampa Medical Group Pa
    Tampa, Florida 33614, United States
  • Atlanta Dermatology, Vein and Research Center, PC
    Alpharetta, Georgia 30022, United States
  • Arthritis and Rheumatology of Georgia
    Atlanta, Georgia 30342, United States
  • Sonora Clinical Research, LLC
    Boise, Idaho 83702, United States
  • Rockford Orthopedic Associates, LLC
    Rockford, Illinois 61107, United States
  • The Arthritis Center
    Springfield, Illinois 62704, United States
  • Indiana. University
    Indianapolis, Indiana 46202, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland 21740, United States
  • Clinical Pharmacology Study Group
    Worcester, Massachusetts 01605, United States
  • Justus Fiechtner MD PC
    Lansing, Michigan 48910, United States
  • Heartland Clinical Research, Inc.
    Omaha, Nebraska 68134, United States
  • Physicians East
    Greenville, North Carolina 27834, United States
  • Unifour Medical Research Associatets LLC
    Hickory, North Carolina 28602, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Clinical Research Center of Reading, LLP
    West Reading, Pennsylvania 19610, United States
  • West Tennessee Research Institute
    Jackson, Tennessee 38305, United States
  • Austin Regional Clinic
    Austin, Texas 78731, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Houston Medical Research
    Houston, Texas 77090, United States
  • Luckster Enterprises
    San Antonio, Texas 78232, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • PharmaSeek
    Middleton, Wisconsin 53562, United States
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Eastern Health Clinical School
    Box Hill, 3128, Australia
  • Repatriation General Hospital
    Daws Park, 5041, Australia
  • Menzies Centre for Population Health Research
    Hobart, 7000, Australia
  • Optimus Clinical Research Pty. Ltd
    Kogarah, 2217, Australia
  • The Queen Elizabeth Hospital
    Woodville, 5011, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU de Liege
    Liège, 4000, Belgium
  • Multiprofile Hospital for Active Treatment Trimontsium
    Plovdiv, 4000, Bulgaria
  • 17 Diagnostic and Consulting Centre Sofia EOOD
    Sofia, 1505, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Ivan Rilski
    Sofia, 1606, Bulgaria
  • Diagnostic-Consultative Center Sveta Anna
    Sofia, 1709, Bulgaria
  • Diagnostic Consulting Center N4
    Varna, 9010, Bulgaria
  • Arthritis Research Centre of Canada
    Vancouver, British Columbia V5Z1L7, Canada
  • PerCuro Clinical Research
    Victoria, British Columbia V8P5P6, Canada
  • Manitoba Clinic
    Winnipeg, Manitoba R3A1M3, Canada
  • St. Clare's Health Care Corporation of St. John's
    St John's, Newfoundland and Labrador A1C-5B8, Canada
  • Ultranova Skincare
    Barrie, Ontario L4M 6L2, Canada
  • William Bensen's Private Practice
    Hamilton, Ontario L8N1Y2, Canada
  • Rheumatology Research Associates
    Ottawa, Ontario K1H1A2, Canada
  • Wilderman Medical Clinic
    Thornhill, Ontario L4J1W3, Canada
  • Probity Medical Research Inc
    Waterloo, Ontario N2J1C4, Canada
  • Darryl Toth's Private Practice
    Windsor, Ontario N8W 1E6, Canada
  • Centre de Rhumatologie St-Louis
    Sainte Foy, Quebec G1W 4R4, Canada
  • Saskatoon Osteoporosis Centre
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Affidea Praha s.r.o
    Praha 11, 148 00, Czechia
  • Revmatologicky ustav
    Praha 2, 128 50, Czechia
  • Revmatologicka Ambulance
    Praha 4, 140 00, Czechia
  • PV - MEDICAL, s.r.o.
    Zlin, 760 01, Czechia
  • East Tallinn Central Hospital
    Tallinn, EE-11412, Estonia
  • North Estonia Regional Hospital
    Tallinn, EE-13419, Estonia
  • Clinical Research Centre Ltd
    Tartu, 50106, Estonia
  • Hotel Dieu
    Nantes Cedex 01, 44093, France
  • Groupe Hospitalier Archet I et II
    Nice, 6002, France
  • Hopital Lariboisiere
    Paris Cedex 10, 75475, France
  • Fondation Hôpital Saint-Joseph
    Paris, 75014, France
  • Qualiclinic kft
    Budapest, 1036, Hungary
  • Synexus Magyarország Kft.
    Budapest, 1036, Hungary
  • Honvéd Kórház - Állami Egészségügyi Központ
    Budapest, 1062, Hungary
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum
    Debrecen, 4032, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Principal SMO Kft.
    Mako, 6900, Hungary
  • MAV Korhaz es Rendelointezet Szolnok
    Szolnok, 5000, Hungary
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Ospedale Luigi Sacco
    Milano, 20157, Italy
  • AOU della II Universita degli Studi di Napoli
    Napoli, 80130, Italy
  • Fondazione PTV Policlinico Tor Vergata
    Roma, 00133, Italy
  • Ospedale Civile Maggiore Borgo Trento
    Verona, 37126, Italy
  • Chungnam National University Hospital
    DaeJeon, 301-721, Korea, Republic of
  • Inha University Hosiptal
    Incheon, 400-711, Korea, Republic of
  • Gachon University Gil Medical Center
    Incheon, 405-760, Korea, Republic of
  • Siauliai Hospital
    Siauliai, LT-76231, Lithuania
  • Waikato hospital
    Hamilton, 3204, New Zealand
  • North Shore Hospital
    Takapuna, 1309, New Zealand
  • Timaru Hospital
    Timaru, 8601, New Zealand
  • Bytomskie Centrum Medyczne Silesiana Sp. z o.o.
    Bialystok, 15-099, Poland
  • Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
    Bydgoszcz, 85-168, Poland
  • Centrum Medyczne Silesiana Sp. z o.o.
    Bytom, 41-902, Poland
  • Synexus SCM Sp. z o.o.
    Gdynia, 81-384, Poland
  • Synexus SCM Sp. z o.o.
    Katowice, Poland, Poland
  • Niepubliczny Zaklad Opieki Zdrowotnej REUMED
    Lublin, 20-582, Poland
  • Prywatna Praktyka Lekarska
    Poznan, 61-397, Poland
  • REUMATIKA-Centrum Reumatologii Niepubliczny Zaklad Opieki Zdrowotnej
    Warszawa, 00-235, Poland
  • Synexus SCM Sp. z o.o. Oddz. Warszawa
    Warszawa, 01-192, Poland
  • Synexus SCM Sp. z o.o.
    Wroclaw, 50-088, Poland
  • Sf. Maria Clinical Hospital
    Bucharest, 011172, Romania
  • Emergency County Clinical Hospital
    Cluj-Napoca, 400006, Romania
  • Sf Apostol Andrei Emergency Clinical County Hospital
    Galati, 800578, Romania
  • C.M.I. Dr. Ciornohuz Adriana
    Iasi, 700127, Romania
  • Veterans of Wars Regional Clinical Hospital
    Kemerovo, 650000, Russian Federation

Showing the first 100 of 118 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mease PJ, Kavanaugh A, Ogdie A, Wells AF, Bergman M, Gladman DD, Richter S, Teng L, Jardon S, Smolen JS. Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naive Patients With Psoriatic Arthritis. J Rheumatol. 2022 Jul;49(7):694-699. doi: 10.3899/jrheum.210906. Epub 2022 Apr 15. PubMed 35428720 ↗
  • Wells AF, Edwards CJ, Kivitz AJ, Bird P, Guerette B, Delev N, Paris M, Teng L, Aelion JA. Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naive patients. Rheumatology (Oxford). 2022 Mar 2;61(3):1035-1043. doi: 10.1093/rheumatology/keab449. PubMed 34100922 ↗
  • Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, Teng L, Aelion JA. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018 Jul 1;57(7):1253-1263. doi: 10.1093/rheumatology/key032. PubMed 29635379 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2010 to primary completion in Feb 2013, 26 months.

Results were first posted in Aug 2014, 1 year 5 months after primary completion. A results delay was requested in Jul 2013.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 26 months is close to that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2010
First posted
Mar 2, 2011
StartActual
Dec 9, 2010
Primary completionActual
Feb 21, 2013
CompletionActual
Aug 16, 2017
Results delay requested
Jul 26, 2013
Results first posted
Aug 15, 2014
Last update
Jun 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01307423
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Mar 2, 2011
Start date
Dec 9, 2010
Primary completion
Feb 21, 2013
Completion
Aug 16, 2017
Results posted
Aug 15, 2014
Last update
Jun 14, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apremilast

Start the discussion